Aspargo Laboratories
Englewood
About Aspargo Laboratories
Aspargo Laboratories is a developer of an oral spray that treats erectile dysfunction.Spray formulation offers convenient drug administration, flexible-dose titration, and accessibility for patients with dysphagia (trouble swallowing). The company develops patient-focused solutions and medicines by combining their innovative science and technology. Its initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRACurrently, it has approved for sale in 9 European countries and 8 Latin American countries, with pending approvals in Portugal, Mexico, Italy, Czech Republic, Slovak Republic, Greece, Australia, and China. Applications for approval are planned for Croatia, France, Germany, and Austria.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $67.9M
- Funding stage: Private Equity
- Last round: Private Equity (Mar 2022)
- Website: aspargolabs.com
- Phone: 201-408-4831
Industries & Categories
Biopharma, Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aspargo-laboratories-63421 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.